Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-07-24
2011-11-15
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
08057804
ABSTRACT:
This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.
REFERENCES:
patent: 4709011 (1987-11-01), Cohen et al.
patent: 4762708 (1988-08-01), Cohen et al.
patent: 5955088 (1999-09-01), Ghiasi et al.
patent: 6193984 (2001-02-01), Ghiasi et al.
patent: 2003/0129199 (2003-07-01), Stephenne et al.
patent: WO 01/08701 (2001-02-01), None
patent: WO01/09361 (2001-02-01), None
patent: WO 02/087614 (2002-11-01), None
patent: WO02/092826 (2002-11-01), None
Pepose et al (American Journal of Ophthalmology 141:547-557, 2006).
Stanberry (Herpes 11 Supplement 3: 161A-169A, 2004).
Bernstein (Expert Review of Vaccines 4:615-627, 2005).
Jones et al (Expert Review of Vaccines 2:541-549, 2003).
Stanberry et al (New England Journal of Medicine 347:1652-1661, 2002).
Judson et al (Journal of Virology 77:12639-12645, 2003).
Kostavili et al (Journal of Immunology 158:1763-1771, 1997).
Hook et al (Journal of Virology 80:4038-4046, 2006).
Ashkenazi et al., 1993, “Immunoadhesins”, Int. Rev. Immunol. 10(2-3): 219-27.
Buchwald et al., 1980, “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis”, Surgery 88:507.
Caudy AA et al., 2002 “Fragile X-related protein and VIG associate with the RNA interference machinery”, Genes & Devel 16:2491-96.
Cheon et al., 1994, “High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains”, PNAS USA 91(3):989-93.
Dubin G., E. Socolof, I. Frank and H. M. Freidman, 1991, “Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity”, J. Virol 65:7046-50.
Eisenberg RJ et al., 1985, “Localization of epitopes of herpes simplex virus type 1 glycoprotein D”, J. Virol 53:634-644.
Evan et al., 1985, “Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product”, Molecular and Cellular Biology 5:3610-3616.
Field et al., 1988, “Purification of a RAS-responsive adenyly1 cyclase complex fromSaccharomyces cerevisiaeby use of an epitope addition method”, Mol. Cell. Biol. 8:2159-2165.
Friedman H. M., Cohen G. H., Eisenberg R. J., Seidel C. A., and Cines D. B., 1984, “Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells”. Nature 309:633-5.
Friedman et al., 1996, “Immune evasion properties of herpes simplex virus type 1 glycoprotein gC”, J. Virol. 70:4253-4260.
Ghiasi et al., “Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): Comparative protection against lethal challenge in mice”, J, Virol., Apr. 1994, 68(4):2118-26.
Ghiasi et al., “Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins, Invest. Ophthalmol”, Vis. Sci., Jun. 1995, 36(7)1352-1360.
Goldstein and Weller, 1988, “An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis”, J. Virol. 62:2970-2977.
Heidaran et al., 1995, “Beta PDGFR-IgG chimera demonstrates that human beta PDGFR Ig-like domains 1 to 3 are sufficient for high affinity PDGF BB binding”, Faseb J. 9(1)140-5.
Hook et al., 2006, “Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin m antibody”, J. Virol. 80:4038-4046.
Hopp et al., 1988, “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification”. BioTechnology 6:1204-1210.
International Search Report of Application No. PCT/US07/26352 issued on Mar. 25, 2008.
Jiang C et al., “Mutations thar decrease DNA binding of the processivity factor of the herpes simplex virus DNA polymerase reduce viral yield, alter the kinetics of viral DNA replication, and decrease the fidelity of DNA replication”, J. Virol., Apr. 2007, 81(7):3495-502.
Jones et al., “Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease”, Herpes, Apr. 2004, 11(1):12-17.
Judson KA et al., “Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection”, J. Virol. 77:12639-45, 2003.
Kase at al., 1999, “Human mannan-binding lectin inhibits the infection of influenza A virus without complement”, Immunology 97:385-392.
Klepeis et al., 2003, “Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity”, J. Am. Chem. Soc. 125:8422-8423.
Kostavasili I., Sahu A., Freidman H. M., Eisenberg R. J., Cohen G. H. and Lambris J. D. , 1997, “Mechanism of complement inactivation by glycoprotein C of herpes simplex virus”, J. Immunol. 158:1763-71.
Labetoulle M et al., “Neuronal propagation of HSV1 from the Oral mucosa to the eye”, Invest Ophthalmol Vis Sci. Aug. 2000; 41(9):2600-6.
Lambiase A et al. “Topical treatment with nerve growth factor in an animal model of herpetic keratitis”, Grafes Arch Clin. Exp. Ophthalmol., May 4, 2007.
Langur, Supra Sefton, 1987, “Implantable Pumps”, CRC Crit. Ref, Biomed. Eng. 14:201.
Larochelle et al., 1995, “Specific receptor detection by a functional keratinocyte growth factor—immunoglobulin chimera”, J. Cell Biol. 129(2):357-66.
Lubinski et al., 1998, “Viral interference with antibody and complement”, Seminars in Cell & Developmental Biology 9:329-37.
Lubinski et al, 1999, “In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC”, J. Exper Med 190:1637-46.
Lubinski et al, 2002, “Herpes simplex virus type 1 evades the effects of antibody and complement in vivo”, J. Virol 76:9232-41.
Lubinski et al, 1998, “Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo”, J. Virol 72:8257-63.
Lutz-Freyermuth et al., 1990, “Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the UI Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA”, Proc. Natl. Acad. Sci. USA, 87:6393-6397.
Majumdar S et al., “Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations”, J. Ocul Pharmacol Ther. Dec. 2005; 21(6):463-74.
Martin et al., 1992, “GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Channel Currents”, Science 255:192-194.
Nagashunmugam et al., “In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc Receptor”, J. Virol. 72:5351-9, 1998.
Nagot et al., “Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus”, N. Engl. J. Med., Feb. 22, 2007, 356(8):790-9.
Nesburn et al., “Vaccine therapy for ocular herpes simplex virus (HSV) Infection: perlocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits”, J. Virol., Aug. 1994, 68(8):5084-5092.
Ouedraogo A et al., “Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial”, AIDS, Nov. 28, 2006; 20(18):2305-13.
Paborsky et
Awasthi Sita
Friedman Harvey
Lubinski John
Cohen Mark S.
Mosher Mary E
Pearl Cohen Zedek Latzer LLP
The Trustees of the University of Pennsylvania
LandOfFree
Herpes simplex virus combined subunit vaccines and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes simplex virus combined subunit vaccines and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes simplex virus combined subunit vaccines and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288688